Assembly Biosciences FY 2024 net loss narrows to $40.2M; pipeline advancing with multiple data readouts in 2025

ASSEMBLY BIOSCIENCES, INC.

Net loss $40.2M ($6.69/share) narrowed from $61.2M ($13.38/share) in 2023; collaboration revenue $28.5M vs $7.2M.
Cash $112.1M at year-end; projected to fund operations into mid-2026.
Received $20.1M equity investment and $10M accelerated funding from Gilead.
Phase 1b data for ABI-4334 (HBV capsid modulator) showed mean 2.9 log10 IU/mL HBV DNA decline in 150mg cohort.
Interim Phase 1b efficacy data for ABI-5366 and ABI-1179 (genital herpes) expected fall 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.